Buy Rinzasip powder for preparing an oral solution Lemon/Vit. With 5g No. 10 in pharmacies
Powder for colds Rinzasip® with a pleasant lemon flavor is a drug that helps relieve the main symptoms of colds, ARVI and flu.
The increased (1) content of paracetamol and the complex of active components included in the composition help reduce temperature, reduce pain in the throat, muscles and joints, fight chills, nasal congestion and runny nose. Caffeine, which is part of the composition, enhances the effect of paracetamol (2), and Vitamin C increases the body's resistance to various adverse environmental factors and strengthens the immune system.
Approved for use from 15 years of age.
1. Compared with preparations containing less than 750 mg of paracetamol. 2. Caffeine accelerates absorption and enhances the analgesic effect of acetaminaphen. B. Renner, D. Clark. Journal of Clinical Pharmacology, 04/18/2007.
Composition per 1 sachet (5 g)
Active ingredients: Ascorbic acid (Vitamin C) - 200 mg, Caffeine - 30 mg, Paracetamol - 750 mg, Phenylephrine hydrochloride - 10 mg, Pheniramine maleate - 20 mg.
Excipients:
- orange: citric acid 200.0 mg, sodium saccharinate 40.0 mg, sodium citrate 500.0 mg, sucrose 3062.5 mg, sunset yellow dye (E110) 7.5 mg, orange flavor 150.0 mg; - citric: citric acid 200.0 mg, sodium saccharinate 40.0 mg, sodium citrate 500.0 mg, sucrose 3136.0 mg, quinoline yellow dye (E104) 1.0 mg, lemon flavor 83.0 mg; — blackcurrant: citric acid 200.0 mg, sodium saccharinate 40.0 mg, sodium citrate 500.0 mg, sucrose 2915.0 mg, azorubine dye (E122) 4.0 mg, fruit flavor (Tutti Frutti) 166.7 mg , raspberry flavor 66.7 mg, blackcurrant flavor 66.7 mg.
Indications for use:
symptomatic treatment of colds, flu, ARVI (fever syndrome, pain syndrome, rhinorrhea).
Directions for use and doses
Inside. Pour the contents of 1 sachet (bag) into a glass, add hot water, stir until completely dissolved and drink (you can add sugar or honey if desired). Taking the drug is recommended 1-2 hours after eating. Adults and children over 15 years of age: take one sachet 3-4 times a day with intervals between doses of 4-6 hours. The maximum daily dose is 4 sachets. The course of treatment without consulting a doctor is no more than 5 days.
Contraindications
Severe atherosclerosis of the coronary arteries, portal hypertension, simultaneous use of tricyclic antidepressants, beta-blockers, monoamine oxidase inhibitors (MAO) and discontinuation of their use less than 2 weeks ago; sucrase/isomaltase deficiency, fructose intolerance, glucose-galactose malabsorption; hypersensitivity to individual components of the drug, as well as to sympathomimetic drugs; simultaneous use of medications containing substances included in the drug; pregnancy, lactation period, children under 15 years of age, alcoholism.
Side effect
Allergic reactions: skin rash, itching, urticaria, angioedema, hypersensitivity reaction, anaphylactic reaction. From the nervous system: headache, dizziness, difficulty falling asleep, insomnia, drowsiness, increased excitability. From the cardiovascular system: increased blood pressure, tachycardia, palpitations. From the digestive system: nausea, vomiting, pain in the epigastric region, dryness of the oral mucosa, increased activity of liver enzymes, hepatotoxic effect. From the senses: mydriasis, accommodation paresis, increased intraocular pressure. From the hematopoietic organs: anemia, thrombocytopenia, agranulocytosis, hemolytic anemia, aplastic anemia, methemoglobinemia, pancytopenia. From the urinary system: nephrotoxicity (renal colic, glycosuria, interstitial nephritis, papillary necrosis), difficulty urinating. Other: bronchospasm, dry nasal mucosa. Serious skin reactions: Very rare: - Acute generalized exanthematous pustulosis (AGEP). Acute condition with the development of pustular rashes. It is characterized by fever and diffuse erythema, accompanied by burning and itching. Swelling of the face, hands and mucous membranes may occur; — Stevens-Johnson syndrome (SJS) (malignant exudative erythema). A severe form of erythema multiforme, in which blisters appear on the mucous membrane of the mouth, throat, eyes, genitals, and other areas of the skin and mucous membranes. - Toxic epidermal necrolysis (TEN, Lyell's syndrome). The syndrome is a consequence of extensive apoptosis of keratinocytes, which leads to the peeling of large areas of skin at the dermoepidermal junction. The affected skin looks like it has been scalded by boiling water. If you notice one of the side effects described above, you should stop taking the drug and consult a doctor immediately!
Overdose
In case of overdose, consult a doctor immediately. Prompt medical attention is critical, even if you do not notice any signs or symptoms. Ascorbic acid: Symptoms of acute overdose: diarrhea and other gastrointestinal disorders. Symptoms of chronic intoxication with ascorbic acid: impaired excretory function of the kidneys, formation of kidney stones, decreased capillary permeability (possible deterioration of tissue trophism, increased blood pressure, hypercoagulation, development of microangiopathies, impaired iron metabolism), erosion of tooth enamel. Caffeine: Symptoms of acute overdose: abdominal pain, nausea, vomiting, fever, chills, headache, agitation, insomnia, irritability, loss of appetite, weakness, tremor, anxiety, altered consciousness, delirium, hallucinations, increased blood pressure followed by hypotension, tachycardia, tachypnea, hypokalemia, hyponatremia, hyperglycemia, metabolic acidosis, epileptic seizures, convulsions, myoclonus and rhabdomyolysis, supraventricular and ventricular arrhythmias. Symptoms of chronic caffeine intoxication (“caffeineism”): irritability, insomnia, anxiety, emotional lability, chronic abdominal pain. Pheniramine: Symptoms: central nervous system depression, hyperthermia, anticholinergic syndrome (mydriasis, flushing, fever, dry mouth, urinary retention, intestinal paresis), tachycardia, hypotension, hypertension, nausea, vomiting, psychomotor agitation, disorientation, hallucinations, psychosis , convulsions, arrhythmias. Rarely, patients with agitation, seizures, or comatose patients develop rhabdomyolysis and renal failure. Phenylephrine: Symptoms: headache, nausea, vomiting, irritability, agitation, insomnia, psychosis, convulsions, palpitations, tachycardia, increased blood pressure, reflex bradycardia. Paracetamol: Symptoms that appear after taking more than 7.5-10 g: during the first 24 hours after taking - pallor of the skin, nausea, vomiting, anorexia, abdominal pain, increased prothrombin time, impaired glucose metabolism, hypokalemia, metabolic acidosis (in including lactic acidosis). Symptoms of liver dysfunction may appear 12-48 hours after an overdose: increased activity of “liver” transaminases, hepatonecrosis. In severe cases - liver failure with progressive encephalopathy, coma. Rarely, liver failure develops rapidly and can be complicated by renal failure (tubular necrosis). The threshold for overdose may be lowered in elderly patients and children, in patients taking certain medications (eg, liver microsomal enzyme inducers), alcohol, or who are malnourished. Treatment: gastric lavage, administration of activated charcoal in the first 6 hours after an overdose, administration of SH-group donors and precursors for the synthesis of glutathione - methionine 8-9 hours after an overdose and acetylcysteine - 12 hours later. The need for additional therapeutic measures (further administration of methionine and acetylcysteine) depends on the concentration of paracetamol in the blood, as well as on the time elapsed after its administration. Symptomatic therapy.
Interaction with other drugs
Enhances the effects of monoamine oxidase inhibitors (MAO), sedatives, ethanol. When taken with digoxin or other cardiac glycosides, the risk of arrhythmia and myocardial infarction may increase. Antidepressants, antiparkinsonian drugs, antipsychotic drugs, phenothiazine derivatives increase the risk of developing urinary retention, dry mouth, and constipation. Glucocorticosteroids increase the risk of developing glaucoma. Microsomal oxidation inhibitors (cimetidine) reduce the risk of hepatotoxicity. Metoclopramide and domperidone increase, and cholestyramine reduces the rate of absorption of paracetamol. Paracetamol reduces the effectiveness of diuretic and uricosuric drugs. When administered simultaneously with barbiturates, diphenin, carbamazepine, rifampicin and other inducers of microsomal liver enzymes, the risk of developing the hepatotoxic effect of paracetamol increases. In most patients taking warfarin long-term, infrequent use of paracetamol usually has little or no effect on the international normalized ratio (INR). However, with prolonged regular use, paracetamol enhances the effect of indirect anticoagulants (warfarin and other coumarin derivatives), which increases the risk of bleeding. A single dose of caffeine increases lithium excretion by the kidneys. Abrupt cessation of caffeine may result in increased serum lithium concentrations. When taken simultaneously with monoamine oxidase inhibitors (MAOIs), furazolidone, pheniramine can lead to hypertensive crisis, agitation, and hyperpyrexia. When taken with MAO inhibitors, phenylephrine may increase blood pressure. Phenylephrine reduces the effectiveness of beta blockers and antihypertensive drugs. It also reduces the hypotensive effect of guanethidine, which, in turn, enhances the alpha-adrenomimetic activity of phenylephrine. Tricyclic antidepressants enhance the adrenomimetic effect of phenylephrine; simultaneous administration of halothane increases the risk of developing ventricular arrhythmia.
special instructions
During the treatment period you should refrain from drinking alcohol. If symptoms worsen or persist for more than 5 days, or if new symptoms appear, you should consult your doctor. The drug may cause drowsiness. The drug contains sucrose, which must be taken into account by patients suffering from diabetes mellitus, as well as those on a hypocaloric diet. 1 single dose of the drug contains from 2915.0 to 3136.0 mg of sucrose, which corresponds to 0.24-0.26 XE. Keep out of the reach of children. If the drug is swallowed by a child, seek immediate medical attention. If the medicine has become unusable or has expired, do not throw it into wastewater or onto the street! Place the medication in a bag and place it in the trash. These measures will help protect the environment!
Vacation:
over the counter
Expiration date, days:
1080
Age:
over 15 years old
Storage conditions
Store in a dry place at a temperature not exceeding 25 °C. Keep out of the reach of children.
Description of the drug RINZASIP®
Paracetamol
Enhances the effects of MAO inhibitors, sedatives, ethanol.
The risk of hepatotoxic action of paracetamol increases with simultaneous use of barbiturates, phenytoin, phenobarbital, carbamazepine, rifampicin, isoniazid, zidovudine and other inducers of microsomal liver enzymes.
With long-term regular use of paracetamol, the anticoagulant effect of warfarin and other coumarins may be enhanced, and the risk of bleeding increases. A single use of paracetamol does not have a significant effect.
Metoclopramide increases the rate of absorption of paracetamol and reduces the time to reach its Cmax in the blood plasma. Likewise, domperidone may increase the rate of absorption of paracetamol.
Paracetamol may lead to an increase in T1/2 of chloramphenicol.
Paracetamol can reduce the bioavailability of lamotrigine, which may reduce the effectiveness of lamotrigine due to the induction of its metabolism in the liver.
Absorption of paracetamol may be reduced when used concomitantly with cholestyramine, but the reduction in absorption is not significant if cholestyramine is taken one hour later.
Regular use of paracetamol concomitantly with zidovudine may cause neutropenia and increase the risk of liver damage.
Probenecid affects the metabolism of paracetamol. In patients concomitantly using probenecid, the dose of paracetamol should be reduced.
The hepatotoxicity of paracetamol increases with prolonged excessive consumption of ethanol (alcohol).
Paracetamol may interfere with the results of the uric acid test using the phosphotungstate precipitating reagent.
Pheniramine
The effect of other substances on the central nervous system (for example, MAO inhibitors, tricyclic antidepressants, alcohol, antiparkinsonian drugs, barbiturates, tranquilizers and narcotic drugs) may be enhanced. Pheniramine may inhibit the action of anticoagulants.
Phenylephrine
Phenylephrine can potentiate the effect of MAO inhibitors and cause a hypertensive crisis.
Concomitant use of phenylephrine with other sympathomimetic drugs or tricyclic antidepressants (eg, amitriptyline) may lead to an increased risk of adverse cardiovascular reactions.
Phenylephrine may reduce the effectiveness of beta blockers and other antihypertensive drugs (eg, debrisoquine, guanethidine, reserpine, methyldopa). There may be an increased risk of hypertension and other cardiovascular side effects.
Concomitant use of phenylephrine with digoxin and cardiac glycosides may increase the risk of cardiac arrhythmias or myocardial infarction.
Concomitant use of phenylephrine with ergot alkaloids (ergotamine and methysergide) may increase the risk of ergotism.
When used simultaneously with barbiturates and primidone, the excretion of ascorbic acid in the urine increases.
Caffeine
Caffeine accelerates the absorption of ergotamine.
RINZASIP FOR CHILDREN
Overdose
In case of overdose, consult a doctor immediately.
Prompt medical attention is critical, even if you do not experience any signs or symptoms.
Pheniramine
Symptoms:
convulsions, impaired consciousness, coma.
Paracetamol
Symptoms
(caused mainly by paracetamol), in adults and children over 12 years of age, appear after taking more than 7.5 - 10 g within 8 hours. Deaths are rare (less than 3-4% of untreated cases) and occur with doses ≥ 15 g of paracetamol. In children under 12 years of age, acute overdose of ≤150 mg/kg paracetamol is not associated with hepatotoxicity.
During the first 24 hours after administration - anorexia, nausea, vomiting, abdominal pain, increased sweating, pallor and general malaise.
Symptoms of liver dysfunction may appear 12-48-72 hours after an overdose: increased activity of “liver” transaminases, hepatonecrosis. In severe cases - liver failure with progressive encephalopathy, coma. Rarely, liver failure develops rapidly and can be complicated by renal failure (tubular necrosis). In case of overdose with a slow-release paracetamol preparation, it is advisable to additionally determine the concentration of paracetamol in plasma 4-6 hours after determining the initial concentration of paracetamol in plasma. Severe hepatotoxicity or death has been extremely rare during acute paracetamol overdose in young children, possibly due to differences in the metabolic pathways of paracetamol.
The following are clinical events associated with paracetamol overdose that, when considered in relation to overdose, are expected, including death due to fulminant liver failure or its sequelae. The following clinical consequences of acute liver failure caused by an overdose of paracetamol (in adults and adolescents over 12 years of age, taking > 7.5 g paracetamol over 8 hours, in children under 12 years, taking > 150 mg/kg paracetamol over 8 hours) are expected: sepsis, fungal infection, bacterial infection, disseminated intravascular coagulation, coagulopathies, thrombocytopenia, hypoglycemia, metabolic acidosis, lactic acidosis, coma, encephalopathy, cerebral edema, cardiomyopathy, hypotension, respiratory failure, pancreatitis, gastrointestinal bleeding, acute renal failure ( tubular necrosis), multiple organ failure.
The threshold for overdose may be lowered in children, in patients taking certain medications (eg, liver microsomal enzyme inducers), alcohol, or who are malnourished.
Treatment:
gastric lavage, administration of activated charcoal in the first 6 hours after an overdose, administration of SH-group donors and precursors for the synthesis of glutathione - methionine 8 - 9 hours after an overdose and acetylcysteine after 12 hours. The need for additional therapeutic measures (further administration of methionine and acetylcysteine) determined by the concentration of paracetamol in the blood, as well as the time elapsed after taking it. Symptomatic therapy.
Rinzasip
Rinzasip (paracetamol + phenylephrine + pheniramine + caffeine) is a combined Indian drug for symptomatic (directed at the effect, not the cause) treatment of acute respiratory diseases, more often popularly referred to as “colds”. The action of rinzasip is determined by the quartet of active ingredients included in its composition, each of which is worthy of a separate presentation. The non-narcotic analgesic-antipyretic paracetamol has an analgesic and antipyretic effect: it can effectively relieve the pain syndrome characteristic of colds (sore and sore throat, headaches, joint and muscle pain) and reduce elevated body temperature. The sympathomimetic phenylephrine has a vasoconstrictor effect on peripheral blood vessels, relieves swelling and reduces hyperemia of the mucous membrane of the upper respiratory tract and sinuses. The H1-histamine receptor blocker pheniramine successfully copes with allergic manifestations: it eliminates burning and itching, and also reduces swelling and hyperemia of the mucous membranes of the nasal cavity, eyes, and sinuses. A pleasant bonus to the action of pheniramine is the elimination of the phenomenon of exudation, which prevents the development of inflammation. Caffeine has a stimulating effect on the central nervous system, which is clinically manifested by an increase in mental and physical performance, as well as a decrease in drowsiness.
Rinzasip is available in the form of powders for the preparation of a solution for oral administration. According to general recommendations, the drug is taken 1 sachet 3-4 times a day, with 4-6 hour intervals between doses. The maximum daily therapeutic “threshold” is 4 sachets per day. The duration of the medication course should not exceed 4-5 days. The optimal time to take is 1-2 hours after a meal, along with a sufficient amount of liquid. Method of preparing the solution: the contents of 1 sachet are dissolved in a glass of hot water and stirred vigorously until the powder is completely dissolved. You can add sugar or honey to taste.
The use of Rinzasip imposes certain restrictions on patients. Thus, during treatment you should refrain from consuming ethanol in any form, as well as anxiolytic (“anti-anxiety”) drugs. The combined use of drugs containing paracetamol is not allowed (rinzasip already contains it, so additional addition of this substance to the pharmacological “diet” may increase the risk of side effects). If the patient's condition does not improve after 3-5 days of pharmacotherapy, a mandatory medical consultation is necessary. Combining rinzasip with antiparkinsonian drugs, antidepressants, and antipsychotic drugs can cause problems with diuresis, constipation, and hyposalivation. When rinzasip is used together with glucocorticosteroids, the risk of developing glaucoma increases. Paracetamol contained in the drug may reduce the effectiveness of diuretics. Tricyclic antidepressants (imipramine, desipramine, amitriptyline) potentiate the adrenomimetic effect of phenylephrine.
It is no secret that combined soluble powders for relieving cold symptoms are among the most popular drugs among the population, especially in the autumn-winter period. Over-the-counter medications, such as Rinzasip, often contain different doses of the same pharmacologically active ingredients. But the effectiveness of the drug is largely determined by the doses of the active substances included in its composition. Thus, the same paracetamol is a “regular” of many anti-cold combinations and one of the safest analgesics-antipyretics: not all drugs its dose corresponds to the dose recommended by WHO (0.5–1 g for 4 “daily” doses, which is equivalent to daily 2–4 g). Rinzasip is one of those drugs that meets WHO recommendations for paracetamol content. It, along with Grippoflu, Coldrex, Maxicold, Rinicold, is one of the most affordable.
Rinzasip®
In case of overdose, consult a doctor immediately.
Prompt medical attention is critical, even if you do not experience any signs or symptoms.
Caffeine
Symptoms of acute overdose: abdominal pain, vomiting, feeling of heat, facial flushing, fever, chills, agitation, insomnia, irritability, loss of appetite, weakness, tremor, increased muscle tone, state of altered consciousness, delirium, hallucinations, increased blood pressure followed by arterial hypotension, tachycardia, tachypnea, increased diuresis, hypokalemia, hyponatremia, hyperglycemia, metabolic acidosis, convulsions, myoclonus and rhabdomyolysis, supraventricular and ventricular arrhythmias.
Symptoms of chronic caffeine intoxication, “caffeineism”: irritability, insomnia, anxiety, emotional lability, chronic abdominal pain.
Pheniramine
Symptoms: central nervous system depression, hyperthermia, anticholinergic syndrome (mydriasis, flushing, fever, dry mouth, urinary retention, intestinal paresis), tachycardia, arterial hypotension, arterial hypertension, nausea, vomiting, agitation, disorientation, hallucinations, psychosis, convulsions, arrhythmias. Rarely, patients with agitation, seizures, or comatose patients develop rhabdomyolysis and renal failure.
Phenylephrine
Symptoms: nausea, vomiting, irritability, agitation, insomnia, psychosis, convulsions, palpitations, tachycardia, increased blood pressure, reflex bradycardia.
Paracetamol
Symptoms appear after taking more than 7.5-10 g: during the first 24 hours after taking - pale skin, nausea, vomiting; anorexia, abdominal pain; increased prothrombin time, impaired glucose metabolism, hypokalemia and metabolic acidosis (including lactic acidosis).
Symptoms of liver dysfunction may appear 12-48 hours after an overdose: increased activity of “liver” transaminases, hepatonecrosis. In severe cases - liver failure with progressive encephalopathy, coma. Rarely, liver failure develops rapidly and can be complicated by renal failure (tubular necrosis).
Treatment: gastric lavage, administration of activated carbon in the first 6 hours after an overdose, administration of SH-group donors and precursors for the synthesis of glutathione - methionine 8-9 hours after an overdose and acetylcysteine after 12 hours. The need for additional therapeutic measures (further administration of methionine and acetylcysteine) is determined by the concentration of paracetamol in the blood, as well as the time elapsed after its administration. Symptomatic therapy.
The threshold for overdose may be lowered in elderly patients and children, in patients taking certain medications (eg, liver microsomal enzyme inducers), alcohol, or who are malnourished.
Rinzasip with vitamin C por d/prig solution vn lemon 5 g x10
Pharmacological action The combined drug has antipyretic, analgesic, alpha-adrenergic, vasoconstrictor and antihistamine effects, eliminates the symptoms of “colds”. Paracetamol is a non-narcotic analgesic that blocks cyclooxygenase, mainly in the central nervous system, affecting the centers of pain and thermoregulation, and has an analgesic and antipyretic effect. Phenylephrine is an alpha-adrenergic agonist with a moderate vasoconstrictor effect. Reduces swelling and hyperemia of the mucous membranes of the upper respiratory tract and paranasal sinuses. Pheniramine is an H1-histamine receptor blocker. Has an antiallergic effect: eliminates itching of the eyes, nose and throat, swelling and hyperemia of the mucous membranes of the nasal cavity, nasopharynx and paranasal sinuses, reduces exudative manifestations. Caffeine has a stimulating effect on the central nervous system, enhances the effect of analgesics, eliminates drowsiness and fatigue, increases physical and mental performance, reduces fatigue and drowsiness. Ascorbic acid (vitamin C) is involved in the regulation of redox processes, carbohydrate metabolism, blood clotting, tissue regeneration, in the synthesis of steroid hormones, reduces vascular permeability and increases the body's resistance to various adverse environmental factors.
Pharmacokinetics Data on the pharmacokinetics of the drug Rinzasip® with vitamin C are not provided.
Indications for use of the drug RINZASIP® WITH VITAMIN C - symptomatic treatment of colds, flu, acute respiratory viral infections (fever, pain, rhinorrhea).
Dosage regimen Adults and children over 15 years of age are prescribed 1 sachet 3-4 with intervals between doses of 4-6 hours. The maximum daily dose is 4 sachets. The course of treatment without consulting a doctor is no more than 5 days. Before use, the contents of 1 sachet should be poured into a glass, pour hot water, stir until completely dissolved and drink (you can add sugar or honey if desired).
Side effects Allergic reactions: skin rash, itching, urticaria, angioedema. From the nervous system: dizziness, difficulty falling asleep, increased excitability. From the cardiovascular system: increased blood pressure, tachycardia. From the digestive system: nausea, vomiting, pain in the epigastric region, dryness of the oral mucosa, hepatotoxic effect. From the senses: mydriasis, accommodation paresis, increased intraocular pressure. From the hematopoietic organs: anemia, thrombocytopenia, agranulocytosis, hemolytic anemia, aplastic anemia, methemoglobinemia, pancytopenia. From the urinary system: urinary retention, nephrotoxicity (papillary necrosis). Other: bronchospasm.
Contraindications to the use of the drug RINZASIP® WITH VITAMIN C - simultaneous use of other medications containing substances included in the drug, - simultaneous use of tricyclic antidepressants, MAO inhibitors, beta-blockers, - pregnancy, - lactation, - children's age (up to 15 years), - sucrase/isomaltase deficiency, fructose intolerance, glucose-galactose malabsorption, - hypersensitivity to paracetamol and other components included in the drug.
With caution: severe atherosclerosis of the coronary arteries, arterial hypertension, thyrotoxicosis, pheochromocytoma, diabetes mellitus, bronchial asthma, chronic obstructive pulmonary disease, glucose-6-phosphate dehydrogenase deficiency, blood diseases, congenital hyperbilirubinemia (Gilbert, Dubin-Johnson and Rotor syndromes), hepatic and/or renal failure, angle-closure glaucoma, prostatic hyperplasia.
Use of the drug RINZASIP® WITH VITAMIN C during pregnancy and lactation The drug is contraindicated for use during pregnancy and lactation.
Use for liver dysfunction The drug should be used with caution in case of liver failure
Use for impaired renal function The drug should be used with caution in case of renal failure
Use in children Contraindicated in children under 15 years of age
Special instructions The patient should be warned that in the absence of a therapeutic effect (hyperthermia for more than 3 days and pain for more than 5 days), he should consult a doctor.
The drug contains sucrose, which must be taken into account by patients suffering from diabetes mellitus, as well as patients on a hypocaloric diet. 1 single dose of the drug contains from 2915.0 mg to 3136.0 mg of sucrose, which corresponds to 0.24-0.26 XE.
The patient should be informed that if the medicine has become unusable or has expired, it should not be thrown into wastewater or onto the street. It is necessary to place the medicine in a bag and place it in the trash container. These measures will help protect the environment.
Impact on the ability to drive vehicles and operate machinery
During the period of taking the drug, it is necessary to refrain from driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.
Overdose Symptoms (caused mainly by paracetamol): pallor of the skin, anorexia, nausea, vomiting, hepatonecrosis, increased activity of liver transaminases, increased prothrombin time. Treatment: gastric lavage, administration of activated charcoal, administration of methionine (within 8-9 hours after an overdose) and N-acetylcysteine (within 8-9 hours after an overdose), symptomatic therapy.
Drug interactions Enhances the effects of MAO inhibitors, sedatives, ethanol. Antidepressants, antiparkinsonian drugs, antipsychotic drugs, phenothiazine derivatives - increase the risk of developing urinary retention, dry mouth, and constipation. Glucocorticosteroids increase the risk of developing glaucoma. Paracetamol reduces the effectiveness of uricosuric drugs. Pheniramine simultaneously with MAO inhibitors and furazolidone can lead to hypertensive crisis, agitation, and hyperpyrexia. Tricyclic antidepressants enhance the adrenomimetic effect of phenylephrine; simultaneous administration of halothane increases the risk of developing ventricular arrhythmia. When prescribing the drug simultaneously with barbiturates, phenytoin, carbamazepine, rifampicin and other inducers of microsomal liver enzymes, the risk of developing the hepatotoxic effect of paracetamol increases.
Conditions for dispensing from pharmacies The drug is approved for use as an over-the-counter product.
Conditions and periods of storage The drug should be stored in a dry place, out of reach of children, at a temperature not exceeding 25°C. Shelf life: 3 years.
Release form, composition and packaging
Powder for solution for oral administration (orange) from light orange to orange in color with white and orange inclusions.
1 sachet (5 g) paracetamol 750 mg ascorbic acid (Vit. C) 200 mg caffeine 30 mg pheniramine maleate 20 mg phenylephrine hydrochloride 10 mg
Excipients: citric acid - 200 mg, sodium saccharinate - 40 mg, sodium citrate - 500 mg, sucrose - 3062.5 mg, sunset yellow dye (E110) - 7.5 mg, orange flavor - 150 mg.
5 g - sachet (5) - cardboard packs. 5 g - sachet (10) - cardboard packs. 5 g - sachet (25) - cardboard packs.
Powder for preparing a solution for oral administration (lemon) is light yellow to yellow in color with white and yellow inclusions.
1 sachet (5 g) paracetamol 750 mg ascorbic acid (Vit. C) 200 mg caffeine 30 mg pheniramine maleate 20 mg phenylephrine hydrochloride 10 mg
Excipients: citric acid - 200 mg, sodium saccharinate - 40 mg, sodium citrate - 500 mg, sucrose - 3136 mg, quinoline yellow dye (E104) - 1 mg, lemon flavor - 83 mg.
5 g - sachet (5) - cardboard packs. 5 g - sachet (10) - cardboard packs. 5 g - sachet (25) - cardboard packs.
Powder for the preparation of a solution for oral administration (blackcurrant) is pink to pinkish-red in color with white and red inclusions.
1 sachet (5 g) paracetamol 750 mg ascorbic acid (Vit. C) 200 mg caffeine 30 mg pheniramine maleate 20 mg phenylephrine hydrochloride 10 mg
Excipients: citric acid - 200 mg, sodium saccharinate - 40 mg, sodium citrate - 500 mg, sucrose - 2915 mg, azorubine dye (E122) - 4 mg, fruit flavor (tutti-frutti) - 166.7 mg, raspberry flavor - 66.7 mg, blackcurrant flavoring - 66.7 mg.
5 g - sachet (5) - cardboard packs. 5 g - sachet (10) - cardboard packs. 5 g - sachet (25) - cardboard packs.
